These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32726191)

  • 1. Adjusted win ratio with stratification: Calculation methods and interpretation.
    Gasparyan SB; Folkvaljon F; Bengtsson O; Buenconsejo J; Koch GG
    Stat Methods Med Res; 2021 Feb; 30(2):580-611. PubMed ID: 32726191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials.
    Gasparyan SB; Kowalewski EK; Folkvaljon F; Bengtsson O; Buenconsejo J; Adler J; Koch GG
    J Biopharm Stat; 2021 Nov; 31(6):765-787. PubMed ID: 34551682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A win ratio approach to comparing continuous non-normal outcomes in clinical trials.
    Wang D; Pocock S
    Pharm Stat; 2016 May; 15(3):238-45. PubMed ID: 26970432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Power and sample size evaluation for the Cochran-Mantel-Haenszel mean score (Wilcoxon rank sum) test and the Cochran-Armitage test for trend.
    Lachin JM
    Stat Med; 2011 Nov; 30(25):3057-66. PubMed ID: 22006667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A win ratio approach for comparing crossing survival curves in clinical trials.
    Zheng S; Wang D; Qiu J; Chen T; Gamalo M
    J Biopharm Stat; 2023 Jul; 33(4):488-501. PubMed ID: 36749067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A note on the Hodges-Lehmann estimator.
    Rosenkranz GK
    Pharm Stat; 2010; 9(2):162-7. PubMed ID: 19718773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Event-specific win ratios and testing with terminal and non-terminal events.
    Yang S; Troendle J
    Clin Trials; 2021 Apr; 18(2):180-187. PubMed ID: 33231108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien-Wei-Lachin.
    Zou G; Zou L
    Stat Med; 2024 Oct; ():. PubMed ID: 39415652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rank-based approach to design and analysis of pretest-posttest randomized trials, with application to COVID-19 ordinal scale data.
    Zou G; Smith EJ; Zou L; Qiu SF; Shu D
    Contemp Clin Trials; 2023 Mar; 126():107085. PubMed ID: 36657521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size estimation for the van Elteren test--a stratified Wilcoxon-Mann-Whitney test.
    Zhao YD
    Stat Med; 2006 Aug; 25(15):2675-87. PubMed ID: 16372389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.
    Dong G; Mao L; Huang B; Gamalo-Siebers M; Wang J; Yu G; Hoaglin DC
    J Biopharm Stat; 2020 Sep; 30(5):882-899. PubMed ID: 32552451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Wilcoxon-Mann-Whitney test under scrutiny.
    Fagerland MW; Sandvik L
    Stat Med; 2009 May; 28(10):1487-97. PubMed ID: 19247980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The stratified win ratio.
    Dong G; Qiu J; Wang D; Vandemeulebroecke M
    J Biopharm Stat; 2018; 28(4):778-796. PubMed ID: 29172988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group sequential monitoring of distribution-free analyses of repeated measures.
    Lachin JM
    Stat Med; 1997 Mar; 16(6):653-68. PubMed ID: 9131754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjusting win statistics for dependent censoring.
    Dong G; Huang B; Wang D; Verbeeck J; Wang J; Hoaglin DC
    Pharm Stat; 2021 May; 20(3):440-450. PubMed ID: 33247544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
    Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
    Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomization-based nonparametric methods for the analysis of multicentre trials.
    LaVange LM; Durham TA; Koch GG
    Stat Methods Med Res; 2005 Jun; 14(3):281-301. PubMed ID: 15969304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of inferential methods for the net benefit and win ratio statistics.
    Verbeeck J; Ozenne B; Anderson WN
    J Biopharm Stat; 2020 Sep; 30(5):765-782. PubMed ID: 32097079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The stratified win statistics (win ratio, win odds, and net benefit).
    Dong G; Hoaglin DC; Huang B; Cui Y; Wang D; Cheng Y; Gamalo-Siebers M
    Pharm Stat; 2023; 22(4):748-756. PubMed ID: 36808217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wilcoxon-Mann-Whitney test: stratify or not?
    Qu Y; Zhao YD; Rahardja D
    J Biopharm Stat; 2008; 18(6):1103-11. PubMed ID: 18991110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.